ASCO and the Association of Community Cancer Centers jointly released recommendations addressing the lack of equity, diversity, and inclusion in cancer clinical trials.
From 1999 to 2019, rates of cancer deaths declined steadily among Black people in the United States. Nevertheless, in 2019, Black people still had considerably higher rates of cancer death than people in other racial and ethnic groups, according to a large epidemiologic study led by NCI researchers.
The COVID-19 pandemic has demonstrated that real-world data is an indispensable tool healthcare professionals should use to rapidly respond to emerging gaps in care delivery.
In a panel discussion this week, five leaders in oncology proposed an action plan for tackling cancer health disparities and enhancing health equity.
The Association of Community Cancer Centers is establishing two efforts targeted at improving cancer screening, care, and mortality rates for the Appalachian region of the U.S.
FDA is asking sponsors of all investigational medical products to focus on including diverse patients throughout the clinical development process.
Deaths from uterine cancer are rising in the U.S., and are highest among non-Hispanic Black women, according to a new study led by researchers at NCI. The higher death rates are related to the rising incidence of aggressive subtypes of uterine cancer.
Two studies led by researchers at the American Cancer Society showed an increase in the use of proton beam therapy for patients with cancer in the U.S. during the past decade.
A study led by researchers at ACS showed cancer survivors in the United States who reported medical financial hardship have a higher mortality risk than cancer survivors without financial hardship. Medical financial hardship was measured as problems affording health care or delaying or forgoing any health care due to cost in the past 12 months.
Findings led by researchers at the American Cancer Society show that five-year survivors of adolescent and young adult cancer in the United States have a higher risk of developing and nearly double the risk of dying from a new primary cancer as the general population.
